Home Breach of Trust Remdesivir


Dr Bryan Ardis in early 2020 looked into remdesivir, on the back of losing his father-in-law to this very drug in February 2020,

by USA Citizens Network
0 comment


17 April 2022

Remdesivir is “a nucleotide analogue prodrug that inhibits viral RNA polymerases,” (an intravenous anti-viral drug) made by Gilead Sciences that was pulled from an Ebola trial due to it increasing mortality. [2]

Dr Bryan Ardis in early 2020 looked into remdesivir, on the back of losing his father-in-law to this very drug in February 2020, and revealed to the world that the NIH’s promotion of remdesivir as the only allowed hospital treatment for COVID-19 was in fact increasing mortality – a death that was certified as a COVID-19 death! Dr Ardis provides his overview of remdesivir findings at the Grand Jury inquiry

Australia’s TGA granted provisional registration for remdesivir (Veklury) in early 2020. [1]

Remdesivir stories at protocolkills.com – Their purpose is to inform the people of what hospitals are doing and how to protect yourself and your loved ones – HERE

Following are links to aid with your own research into Remdesivir

The Fauci promoted NIH Remdesivir RCT clinical trail started Feb 21, 2020 enrolling 1100 individuals, it concluded that patients had a “31% better chance of recovering and getting out of the hospital”
They changed the trial endpoints from reduced mortality, to days in hospital. They unblinded patient and discharged treatment group from hospital early!
Anyone who came to a hospital and “diagnosed” with COVID-19 were put on remdesivir. Hospitals incentivised, patients restrained to beds with cable ties, drugged with morphine, starved, dehydrated, phone remove and isolated from their family – the average time to death on remdesivir is 9 days! = torture
Patients threatened if they leave hospital against medical advice, insurance won’t cover hospital cost = blackmail
Lawyers have thousands of alarmingly similar testimonies across 32 states.
Some clients received 30-40 different drugs, many contraindicated with remdesivir!
September 7, 2022 – Towards The Light: Remdesivir deaths press conference – Fresno, California – WATCH

January 21, 2022 – FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19 and to pediatric population down to 3.5kg weight! – READ Three days later monoclonal antibodies were removed as an early treatment option!

January 27, 2022- NEJM – Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients (3-day course remdesivir) – READ

October 18, 2021 – The Blaze: Horowitz: The $cience of remdesivir vs. ivermectin: A tale of two drugs – READ, ARCHIVE

“A tale of two drugs. One has become the standard of care at an astronomical cost despite studies showing negative efficacy, despite causing severe renal failure and liver damage, and despite zero use outpatient. The other has been safely administered to billions for river blindness and now hundreds of millions for COVID throughout the world and has turned around people at death’s doorstep for pennies on the dollar.”
October 13, 2021 – Cardiovascular Toxicity: Potential cardiotoxic effects of remdesivir on cardiovascular system: a literature review. (Remdesivir is substantially more cardio-toxic than chloroquine) – READ, WATCH

July 8, 2021 – In the US “COVID-19 Treatment Guidelines”, the NIH knows remdesivir is associated with renal toxicity – See Table 2e pg. 153 – HERE, ARCHIVE, WATCH The table is now referred to as Table 2f – HERE

April 17, 2021 – India – COVID-19: Remdesivir price slashed by nearly Rs 2000 post govt intervention – READ

April 2021 – Remdesivir and acute renal failure: a potential safety signal from disproportionality analysis of the WHO safety database. (Remdesivir was found to have a 20-fold higher renal failure rate compared to three comparable drugs: hydroxychloroquine, tocilizumab, and lopinavir/ritonavir) – READ, WATCH

November 20, 2020 – NBC News: Remdesivir shouldn’t be used on hospitalized COVID-19 patients, WHO advises (as there is no evidence it improves survival or reduces the need for ventilation). “Remdesivir has potential side-effects on the kidneys, according to data Gilead shared with the European Medicines Agency” – READ, ARCHIVE, READ2

November 5, 2020 – NEJM: Remdesivir for the Treatment of Covid-19 — Final Report by Beigel et al [NIH paper] – READ

Dr Alexander discussion re paper – SUBSTACK

Study design tampering “they made a non patient important outcome (time to recovery), the primary outcome.”
“the NIH highly touted and flaunted study that did not report or focus on patient-important objective outcomes and only on reduced time to recovery, was deeply flawed methodologically.” – REF
November 4, 2020 – Under it’s New COVID-19 Treatments Add-On Payment (NCTAP) US CMS.gov provides a 20% bonus payment on the entire hospital bill, just if they administer remdesivir. – LINK, LINK2, WATCH Compared to other treatments remdesivir is below inferior (look at cost of the drugs vs those approved!)!

October 23, 2020 – NBC News: FDA approves first drug for COVID-19: remdesivir. No other Covid-19 drugs have received FDA approval. – READ

October 22, 2020 – The Highwire Ep 186: FAUCI’S REMDESIVIR ‘FALLS FLAT’ – WATCH, BITCHUTE, FULL

“In April, Dr. Fauci said the repurposed antiviral, Remdesivir, showed a “clear-cut, significant, positive effect in diminishing the time to recovery.” However, the WHO has now released the findings of its ‘Solidarity Trial,’ encompassing 400 hospitals around the world. Results indicate the drug has ‘fallen flat,’ prompting the WHO to declare it has “little to no effect” on hospitalized COVID-19 patients.”
“This is just a drug looking for a purpose” says Del
October 20, 2020 – Reuters: EU makes 1 billion-euro bet on Gilead’s COVID drug before trial results – The European Union agreed to pay > 1 billion euros (USD$1.2 billion) to Gilead for a six-month supply of its antiviral drug remdesivir, before the publication of final results of the biggest trial of the COVID-19 medication “The agency [WHO] is investigating remdesivir’s potential adverse effects on kidneys”. – READ

October 16, 2020 – Science: Remdesivir and interferon fall flat in WHO’s megastudy of COVID-19 treatments – READ, ALT

October 15, 2020 – PRESS RELEASE: Gilead Sciences Statement on the Solidarity Trial – READ, ARCHIVE

“We are concerned that the data from this open-label global trial have not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design.”
October 15, 2020 – NEJM: Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results – READ, preprint date – READ2, WHO SOLIDARITY TRIAL COVID-19 core protocol – PDF

WHO funded SOLIDARITY trial included: “405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug.”
ALL had “little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.”
The regimen for remdesivir (intravenous) was 200 mg on day 0 and 100 mg on days 1 through 9.
[note: hydroxychloroquine was not being used in patients this late by the frontline doctors – MORE]
October 3, 2020 – The Lancet correspondence: Remdesivir and COVID-19 – READ

August 13, 2020- Clin. Epid. & Global Heath: Remdesivir and its antiviral activity against COVID-19: A systematic review – READ

July 10, 2020 – Nature Medicine: Extrapulmonary manifestations of COVID-19 – READ, WATCH

These are all side effects of remdesivir, yet the study concludes they are attributed to the virus SARS-CoV-2:

“Although COVID-19 is most well known for causing substantial respiratory pathology, it can also result in several extrapulmonary manifestations. These conditions include thrombotic complications, myocardial dysfunction and arrhythmia, acute coronary syndromes, acute kidney injury, gastrointestinal symptoms, hepatocellular injury, hyperglycemia and ketosis, neurologic illnesses, ocular symptoms, and dermatologic complications.”
June 30, 2020 – Case report study of the first five COVID-19 patients treated with remdesivir in France (the remdesivir treatment was interrupted in 4 out of 5 patients) – READ, WATCH

June 11, 2020 – NEJM – Compassionate Use of Remdesivir for Patients with Severe COVID-19 (study by Gilead 10 days of drug of which 60% patients reported adverse events including acute kidney failure) – READ, WATCH

May 28, 2020 – The Lancet – Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial by Wang et al – READ, PDF, (note this was in preprint April 29, 2020), Dr Alexander – SUBSTACK

“In adult patients admitted to hospital for severe COVID-19, “remdesivir was not associated with statistically significant clinical benefits.”
Furthermore, and very alarmingly, adverse events were reported in “102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients.” –REF
May 7, 2020 – Japan approves Gilead Sciences’ remdesivir as COVID-19 drug – READ

April 30, 2020 – The Highwire Ep 161: CORONAVIRUS: A NATION DIVIDED – segment on Chloroquine vs. Remdesivir – WATCH, FULL

February 28, 2020 – Scientific America: A Promising Antiviral Is Being Tested for the Coronavirus—but Results Are Not Yet Out – READ, ARCHIVE

The drug remdesivir is effective against many other viruses, and some experts are optimistic that it—or similar compounds—may work for the pathogen responsible for COVID-19

…”and a malaria drug called chloroquine, which is not an antiviral but has shown some efficacy against COVID-19 in a lab dish. Yet experts say drugs that specifically target other pathogens are unlikely to work well enough.”

“Timothy Patrick Sheahan, an assistant professor of epidemiology at the University of North Carolina Gillings School of Global Public Health, is among those in the U.S. working on antiviral drugs for COVID-19. Like De Clercq, he is skeptical that many of the antivirals already on the market would work.

“I’m doubtful that existing approved medications for other infectious diseases will have some magical property against this new coronavirus,”

Tim Sheahan
[Note Sheahan has a conflict of interest in making this statement as he helped develop remdesivir otherwise known as GS-5734 ]

“Sheahan and his colleagues have published several papers showing that remdesivir is effective against SARS, MERS and related bat coronaviruses, as well as some of the common cold coronaviruses.” – HERE & HERE

“Lisa Gralinski, an assistant professor of epidemiology and colleague of Sheahan’s at the Gillings School,
“I think it will probably be really effective” if you can get it to the patient within the first or second week… But “you’re not going to be able to come in and give this drug to someone who’s approaching end-stage lung disease and improve their outcome.” At that point, the lung damage is no longer being caused by viral replication but is happening because of the body’s own immune response—so an antiviral would likely not be effective. Yet if enough of the drug is available, Gralinski says, she would give it at the time of diagnosis.”

“…if we already have something that’s mostly through development, like has luckily been the case with remdesivir, you can get it to people very rapidly.” Even if the drug proves to be effective, however, producing enough of it and distributing it to everyone in need is not guaranteed.”

March 5, 2020 – NEJM: First Case of 2019 Novel Coronavirus in the United States – Holshue et al – READ

February 26, 2020 – PRESS RELEASE: Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19 – READ

“Gilead’s trials will evaluate two dosing durations of the drug, which is given intravenously. The randomized, open-label, multicenter studies will enroll about 1,000 patients mostly in Asia, as well as in countries that have had high numbers of diagnosed cases. The trials are planned to start in March.

These trials are on top of two clinical trials in China’s Hubei province led by the China-Japan Friendship Hospital and a recently launched trial in the U.S. led by the NIAID. Gilead donated the drug and provided scientific expertise for those trials. The China trial data is expected in April.” – REF

February 21, 2020 – ClinicalTrials.gov: Adaptive COVID-19 Treatment Trial – READ, ARCHIVE
That trial will be conducted at up to 50 sites around the world and will test remdesivir against a placebo. – SOURCE

February 6, 2020 – ClinicalTrails. gov: Severe 2019-nCoV Remdesivir RCT – READ, ARCHIVE, SOURCE

February 6, 2020 – New York Times: China Begins Testing an Antiviral Drug [remdesivir] in Coronavirus Patients – READ

February 5, 2020 – ClinicalTrails. gov: Mild/Moderate 2019-nCoV Remdesivir RCT – READ, ARCHIVE

February 5, 2020 – Washington Times: Chinese scientists ask for patent on U.S. drug to fight virus – READ
Gilead, headquartered in Foster City, California, said it applied in 2016 for a Chinese patent on use of remdesivir against coronaviruses and is waiting for a decision.

January 31, 2020 – Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV) – READ

January 21, 2020 – Remdesivir was used on the first COVID-19 patient in the US – INFO

December 12, 2019 – NEJM: A randomized controlled trial of ebola virus disease therapeutics (monoclonal antibodies vs remdesivir), funded by NIAID. [The study showed 28 days of remdesivir increased mortality of 53.1% and pulled from the trial] – READ, WATCH

November 27, 2019 – NIAID: Investigational Drugs Reduce Risk of Death from Ebola Virus Disease
Study Leaders Publish Results from NIH-DRC-WHO Clinical Trial of Four Experimental Therapies – READ

September 2019 – Antiviral Research: Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase – Brown with Baric & Sheahan et al – READ, SOURCE

August 13, 2019 – Clinical Trials Arena: Preliminary findings from the Pamoja Tulinde Maisha (PALM) clinical trial have revealed that two monoclonal antibodies, REGN-EB3 and mAb114, produced a higher chance of survival in Ebola patients. (not remdesivir) – READ

“Reuters noted that around 29% of subjects treated with REGN-EB3 and 34% in the mAb-114 arm died, compared to 49% of those on ZMapp and 53% who received remdesivir.”

August 12, 2019 – Science: Finally, some good news about Ebola: Two new treatments dramatically lower the death rate in a trial (not remdesivir!) – READ

August 9, 2019 – Remdesivir dropped from Ebola trial – TIMELINE

March 6, 2018 – American Society of Microbiology: Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease – Agostini, with Baric & Sheahan et al – READ, SOURCE

August 31, 2017 – Gillings School researchers receive $6M+ grant to fight infectious diseases – (Ralph Baric) – READ

History of Gilead Sciences – LINK

#Gilead #Remdesivir #Dr Bryan Ardis #Ardis #Mortality

Share This

You May Also Like

Leave a Comment

This website uses cookies to improve your experience. We'll assume you're OK with this, but you can opt-out if you wish. Accept Read More